MultNAT® C. difficile Assay
Product Overview
MultNAT® C. difficile Assay is a qualitative nucleic acid-based in vitro diagnostic test intended for the detection of toxin B gene sequences and for the presumptive identification of 027/NAP1/BI
strains of toxigenic Clostridioides difficile from unformed (liquid or soft) stool specimens.
The assay is indicated as an aid in the diagnosis of C. difficile infection (CDI). Detection of 027/NAP1/BI strains is presumptive and for epidemiological purposes only, and should not be used as the sole basis for clinical diagnosis or treatment decisions.
- Fast: Get result from sample in about 59 minutes
- Simple: Fully automated workflow. Sample-in, result-out
- Safe: All-in-one cartridge with integrated UDG anti-contamination system
- Accuracy: Difficile: 50 CFU/swab 027/NAP1/BI: 50 CFU/swab
- Accuracy: Difficile: 50 CFU/swab 027/NAP1/BI: 50 CFU/swab
Ongoing Challenges
Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated diarrhea worldwide, with risk significantly increased following the use of broad-spectrum antibiotics
The emergence of hypervirulent strains, such as PCR ribotype 027/NAP1/BI, is associated with more severe disease, higher recurrence rates, and increased mortality, posing major challenges for clinical management and hospital infection control
Rapid and accurate differentiation between toxigenic C. difficile and hypervirulent strains is critical for timely diagnosis, appropriate treatment, and effective outbreak prevention
Clinical Value
Quickly confirm toxigenic C. difficile infection, enabling timely initiation of targeted therapy
Presumptive identification of hypervirulent 027/NAP1/BI strains helps assess disease severity and recurrence risk
Early detection supports the implementation of enhanced contact precautions to prevent hospital outbreaks
Fast and accurate results guide clinical decision-making, optimizing treatment and reducing complications and healthcare costs
